Superior short-term cholesterol control and achievement of the adult treatment panel III low-density lipoprotein goals with initiation of statin therapy by the time of hospital discharge following acute myocardial infarction

American Journal of Cardiology

Volumn 93, Issue 6, 2004, Pages 776-779

  Bybee, Kevin A ^b   Powell, Brian D ^b   Williams, Brent A ^b   Murphy, Joseph G ^b   Kopecky, Stephen L ^b   Wright, R Scott ^a  

^a MAYO CLINIC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; CLINICAL TRIAL; COMMUNITY; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; FEMALE; FOLLOW UP; HEART MUSCLE ISCHEMIA; HOSPITAL DISCHARGE; HUMAN; INTERMETHOD COMPARISON; LOW FAT DIET; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REDUCTION; RISK ASSESSMENT; TREATMENT OUTCOME;

AGED; CHOLESTEROL; CHOLESTEROL, LDL; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; MINNESOTA; MYOCARDIAL INFARCTION; PATIENT DISCHARGE; PRACTICE GUIDELINES; RESIDENCE CHARACTERISTICS;

EID: 1542407815     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2003.11.059     Document Type: Article

References (20)

1. Scandinavian Simvastatin Study Group. Randomized trial of cholesterol lowering in 4,444 patients with coronary artery disease the Scandinavian Simvastatin Survival Study (4S). Lancet. 344:1994;1383-1389.
2. Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole T.G., Brown L., Warnica J.W., Arnold J.M., Wun C.C., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels (CARE). N Engl J Med. 335:1996;1001-1009.
3. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 339:1998;1349-1357.
4. Albert M.A., Danielson E., Rifai N., Ridker P.M. Effect of statin therapy on C-reactive protein levels. The Pravastatin INflammation/CRP Evaluation (PRINCE) a randomized trial and cohort study. JAMA. 286:2001;64-70.
5. Bustos C., Hernandez-Presa M., Ortego M., Tunon J., Ortega L., Perez F., Diaz C., Hernandez G., Edgido J. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. J Am Coll Cardiol. 32:1998;2057-2064.
6. Beigel Y., Fuchs J., Snir M., Green P., Lurie Y., Djaldetti M. Lovastatin therapy in hypercholesterolemia effect on fibrinogen, hemorrheologic parameters, platelet activity, and red blood cell morphology. J Clin Pharmacol. 31:1991;512-517.
7. Mayer J., Eller T., Brauer P., Solleder E.M., Schafer R.M., Keller F., Kochsiek K. Effects of long-term treatment with lovastatin on the clotting system and blood platelets. Ann Hematol. 64:1992;196-201.
8. 2 synthesis in type IIa hypercholesterolemic patients. Atherosclerosis. 79:1989;79-83.
9. Notarbartolo A., Davi G., Averna M., Barbagallo C.M., Ganci A., Giammarresi C., La Placa F.P., Patrono C. Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia. Arterioscler Thromb Vasc Biol. 15:1995;247-251.
10. Dupuis J., Tardif J.C., Cernacek P., Theroux P. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes the RECIFE (Reduction of Cholesterol in Ischemia and Function of the Endothelium) trial. Circulation. 99:1999;3227-3233.
11. O'Driscoll G., Green D., Taylor R. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation. 95:1997;1126-1131.
12. Aronow H.D., Topol E.J., Roe M.T., Houghtaling P.L., Wolski K.E., Lincoff A.M., Harrington R.A., Califf R.M., Ohman E.M., Kleiman N.S., et al. Effect of lipid-lowering therapy on early mortality after acute coronary syndromes an observational study. Lancet. 357:2001;1063-1068.
13. Bybee K.A., Wright R.S., Williams B., Murphy J., Holmes D., Kopecky S. Effect of concomitant or very early statin administration on in-hospital mortality and re-infarction rates in patients with acute myocardial infarction. Am J Cardiol. 87:2001;771-774.
14. Stenestrand U., Wallentin L. Swedish Register of Cardiac Intensive Care (RIKS-HIA). Early statin treatment following acute myocardial infarction and 1-year survival. JAMA. 285:2001;430-436.
15. Schwartz G.G., Olsson A.G., Ezekowitz M.D., Ganz P., Oliver M.F., Waters D., Zeiher A., Chaitman B.R., Leslie S., Stern T. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes the MIRACL study. JAMA. 285:2001;1711-1718.
16. DeBusk R.F., Miller N.H., Superko H.R., Dennis C.A., Thomas R.J., Lew H.T., Berger W.E., Heller R.S., Rompf J., Gee D., et al. A case-management system for coronary risk factor modification after acute myocardial infarction. Ann Intern Med. 120:1994;721-729.
17. Fonarow G.C., French W.J., Parsons L.S., Sun H., Malmgren J.A. Use of lipid-lowering medications at discharge in patients with acute myocardial infarction data from the National Registry of Myocardial Infarction 3. Circulation. 103:2001;38-44.
18. NCEP Expert Panel. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 28:2001;2486-2497.
19. Muhlestein J.B., Horne B.D., Bair T.L., Li Q., Madsen T.E., Pearson R.R., Anderson J.L. Usefulness of in-hospital prescription of statin agents after angiographic diagnosis of coronary artery disease in improving continued compliance and reduced mortality. Am J Cardiol. 87:2001;257-261.
20. Fonarow G.C., Gawlinski A., Moughrabi S., Tillisch J.H. Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program CHAMP. Am J Cardiol. 87:2001;819-822.